Citations

Showing 10 of 108104 citations.

Lessons From ACST-2
Meschia, James F. , Brott, Thomas G., Meschia, James F , Brott, Thomas G.

Mayo Clinic

Stroke | March 1, 2022 | Volume: 53 | Issue: 4 | Pages: No page available

10.1161/strokeaha.121.037269 | PMID 35227079 Get It

The recent 130-center, international, second ACST trial (Asymptomatic Carotid Surgery Trial) involving 3625 patients found that regardless of whether a patient underwent stenting or endarterectomy, the periprocedural risk of disabling or fatal stroke was about 1% and the 5-year estimated risk of nonprocedural disabling or fatal stroke was 2.5%. With advances in technique, technology, and patient selection, stenting done by appropriately trained and experienced operators can achieve safety and efficacy comparable to endarterectomy for asymptomatic patients. The ongoing CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) will clarify whether revascularization, by either stenting or endarterectomy, remains an important therapeutic goal in the setting of modern intensive medical therapy.
Incidental Visualization of Hypertrophic Vasa Nervorum in a Patient With Peripheral Vascular Disease
Bais, Kimmy , Franco, Michael J., Robards, Christopher B., Erben, Young , Porter, Steven B.

Mayo Clinic

Journal for Vascular Ultrasound | March 1, 2022 | Volume: 46 | Issue: 2 | Pages: 80-81

10.1177/15443167221079386 Get It

Vasa nervorum are the blood vessels which supply adequate oxygen to peripheral nerves. Various vascular pathologies produce inflammatory changes compromising the blood flow through the vasa nervorum. We describe a patient with peripheral vascular disease admitted for below knee amputation who was found to have hypertrophied vasa nervorum in the ipsilateral femoral and popliteal sciatic nerves.
Head and neck synthetic CT generated from ultra‐low‐dose cone‐beam CT following Image Gently Protocol using deep neural network
Yuan, Nimu , Rao, Shyam , Chen, Quan , Sensoy, Levent, Qi, Jinyi , Chen, Quan , Rong, Yi

Mayo Clinic

Medical Physics | March 1, 2022 | Volume: 49 | Issue: 5 | Pages: 3263-3277

10.1002/mp.15585 | PMID 35229904 Get It

AbstractPurposeImage guidance is used to improve the accuracy of radiation therapy delivery but results in increased dose to patients. This is of particular concern in children who need be treated per Pediatric Image Gently Protocols due to long‐term risks from radiation exposure. The purpose of this study is to design a deep neural network architecture and loss function for improving soft‐tissue contrast and preserving small anatomical features in ultra‐low‐dose cone‐beam CTs (CBCT) of head and neck cancer (HNC) imaging.MethodsA 2D compound U‐Net architecture (modified U‐Net++) with different depths was proposed to enhance the network capability of capturing small‐volume structures. A mask weighted loss function (Mask‐Loss) was applied to enhance soft‐tissue contrast. Fifty‐five paired CBCT and CT images of HNC patients were retrospectively collected for network training and testing. The output enhanced CBCT images from the present study were evaluated with quantitative metrics including mean absolute error (MAE), signal‐to‐noise ratio (SNR), and structural similarity (SSIM), and compared with those from the previously proposed network architectures (U‐Net and wide U‐Net) using MAE loss functions. A visual assessment of ten selected structures in the enhanced CBCT images of each patient was performed to evaluate image quality improvement, blindly scored by an experienced radiation oncologist specialized in HN cancer.ResultsAll the enhanced CBCT images showed reduced artifactual distortion and image noise. U‐Net++ outperformed the U‐Net and wide U‐Net in terms of MAE, contrast near structure boundaries, and small structures. The proposed Mask‐Loss improved image contrast and accuracy of the soft‐tissue regions. The enhanced CBCT images predicted by U‐Net++ and Mask‐Loss demonstrated improvement compared to the U‐Net in terms of average MAE (52.41 vs 42.85 HU), SNR (14.14 vs 15.07 dB), and SSIM (0.84 vs 0.87), respectively (, in all paired t‐tests). The visual assessment showed that the proposed U‐Net++ and Mask‐Loss significantly improved original CBCTs (), compared to the U‐Net and MAE loss.ConclusionsThe proposed network architecture and loss function effectively improved image quality in soft‐tissue contrast, organ boundary, and small structure preservation for ultra‐low‐dose CBCT following Image Gently Protocol. This method has potential to provide sufficient anatomical representation on the enhanced CBCT images for accurate treatment delivery and potentially fast online‐adaptive re‐planning for HN cancer patients.
Quo vadis now: Beyond genomics to an era of personalised medicine
Rahman, Shamima , Baumgartner, Matthias R. , Patterson, Marc, Baumgartner, Matthias , Morava, Éva , Patterson, Marc C. , Peters, Verena , Zschocke, Johannes

Mayo Clinic

Journal of Inherited Metabolic Disease | March 1, 2022 | Volume: 45 | Issue: 2 | Pages: 129-131

10.1002/jimd.12487 | PMID 35229313 Get It

Gene expression in lung epithelial cells following interaction with Pneumocystis carinii and its specific life forms yields insights into host gene responses to infection
Kottom, Theodore J. , Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

Microbiology and Immunology | March 1, 2022 | Volume: 66 | Issue: 5 | Pages: 238-251

10.1111/1348-0421.12972 | PMID 35229348 Get It

Abstract Pneumocystis spp. interacts with epithelial cells in the alveolar spaces of the lung. It is thought that the binding of Pneumocystis to host cell epithelium is needed for life cycle completion and proliferation. The effect of this interaction on lung epithelial cells has previously shown that the trophic form of this organism greatly inhibits p34 cdc2 activity, a serine/threonine kinase required for transition from the G 2 to M phase in the cell cycle. To gain further insight into the host response during Pneumocystis pneumonia infection, we used microarray technology to profile epithelial cell (A549) gene expression patterns following Pneumocystis carinii interaction. Furthermore, we isolated separate populations of cyst and trophic forms of P. carinii , which were then applied to the lung epithelial cells. Differential expression of genes involved in various cellular functions dependent on the specific P. carinii life form in contact with the A549 cell was identified. The reliability of our data was further confirmed by Northern blot analysis on a number of selected upregulated or downregulated transcripts. The transcriptional response to P. carinii was dominated by cytokines, apoptotic, and antiapoptosis‐related genes. These results reveal several previously unknown effects of P. carinii on the lung epithelial cell and provide insight into the complex interactions of host and pathogen.
Management of Type 1 Diabetes in Children in the Outpatient Setting
Jackson, S. Craig, Creo, Ana L. , Nofal, Alaa Al , Creo, Ana , Al Nofal, Alaa

Mayo Clinic

Pediatrics In Review | March 1, 2022 | Volume: 43 | Issue: 3 | Pages: 160-170

10.1542/pir.2020-001388 | PMID 35229106 Get It

Genetic Etiologies, Diagnosis, and Management of Neonatal Cystic Kidney Disease
Heidenreich, Leah S. , Bendel‐Stenzel, Ellen , Hanna, Christian , Bendel-Stenzel, Ellen M, Hanna, Christian , Harris, Peter C.

Mayo Clinic

NeoReviews | March 1, 2022 | Volume: 23 | Issue: 3 | Pages: e175-e188

10.1542/neo.23-3-e175 | PMID 35229136 Get It

Fetal kidney development is a complex and carefully orchestrated process. The proper formation of kidney tissue involves many transcription factors and signaling pathways. Pathogenic variants in the genes that encodethese factors and proteins can result in neonatal cystic kidney disease. Advancements in genomic sequencing have allowed us to identify many of these variants and better understand the genetic underpinnings for an increasing number of presentations of childhood kidney disorders. This review discusses the genes essential in kidney development, particularly those involved in the structure and function of primary cilia, and implications of gene identification for prognostication and management of cystic kidney disorders.
Cholestatic liver diseases of genetic etiology: Advances and controversies
Ibrahim, Samar H. , Kamath, Binita M. , Loomes, Kathleen M. , Karpen, Saul J. , Ibrahim, Samar H , Karpen, Saul

Mayo Clinic

Hepatology | March 1, 2022 | Volume: 75 | Issue: 6 | Pages: 1627-1646

10.1002/hep.32437 | PMID 35229330 Get It

Abstract With the application of modern investigative technologies, cholestatic liver diseases of genetic etiology are increasingly identified as the root cause of previously designated “idiopathic” adult and pediatric liver diseases. Here, we review advances in the field enhanced by a deeper understanding of the phenotypes associated with specific gene defects that lead to cholestatic liver diseases. There are evolving areas for clinicians in the current era specifically regarding the role for biopsy and opportunities for a “sequencing first” approach. Risk stratification based on the severity of the genetic defect holds promise to guide the decision to pursue primary liver transplantation versus medical therapy or nontransplant surgery, as well as early screening for HCC. In the present era, the expanding toolbox of recently approved therapies for hepatologists has real potential to help many of our patients with genetic causes of cholestasis. In addition, there are promising agents under study in the pipeline. Relevant to the current era, there are still gaps in knowledge of causation and pathogenesis and lack of fully accepted biomarkers of disease progression and pruritus. We discuss strategies to overcome the challenges of genotype–phenotype correlation and draw attention to the extrahepatic manifestations of these diseases. Finally, with attention to identifying causes and treatments of genetic cholestatic disorders, we anticipate a vibrant future of this dynamic field which builds upon current and future therapies, real‐world evaluations of individual and combined therapeutics, and the potential incorporation of effective gene editing and gene additive technologies.
Vascularized Lymph Node Transfer for the Treatment of Posttraumatic Lower Extremity Lymphedema: A Preliminary Report
Ciudad, Pedro , Huayllani, María T. , Forte, Antonio J. , Escandón, Joseph M. , Manrique, Oscar J. , Boczar, Daniel , Ávila, Francisco R. , Escandón, Joseph M , Forte, Antonio Jorge , Chen, Hung‐Chi

Mayo Clinic

Indian Journal of Plastic Surgery | March 1, 2022 | Volume: 55 | Issue: 01 | Pages: 097-101

10.1055/s-0041-1740520 | PMID 35444749 Get It

Abstract Background Posttraumatic lymphedema develops more frequently than expected and reports on its management are scarce in the literature. We aimed to report the clinical outcomes of a case series of posttraumatic lymphedema patients treated with different vascularized lymph node transfers (VLNTs). Patients and Methods Five patients with secondary posttraumatic lower limb lymphedema treated with VLNT were included in this report. The groin-VLNT (n = 1), supraclavicular-VLNT (n = 2), and gastroepiploic-VLNT (n = 2) were implemented. The average flap area was 69.8 cm2. Patients underwent postoperative complex decompressive therapy for an average of 10.0 months. Results The average mean circumference reduction rate was 24.4% (range, 10.2–37.6%). Postsurgical reduction in the number of infection episodes per year was observed in all patients. The mean follow-up was 34.2 months. Conclusions VLNT is a promising surgical treatment for posttraumatic lymphedema patients. In our report, VLNT has demonstrated to reduce the volume and number of infections per year in posttraumatic lymphedema.
A Five-Day Intensive Treatment for Pediatric Obsessive-Compulsive Disorder: A Multiple Baseline Design Pilot Study
Ollendick, Thomas H. , Farrell, Lara J. , Whiteside, Stephen P. H. , Canavera, Kristin E.

Mayo Clinic

Evidence-Based Practice in Child and Adolescent Mental Health | February 28, 2022 | Volume: 8 | Issue: 1 | Pages: 120-132

10.1080/23794925.2022.2034553 Get It